A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...

A third anti-amyloid, aducanumab (Aduhelm), was fast-tracked for approval in 2021, but the drugmaker took it off the market in early 2024 to focus on other drugs for Alzheimer’s.

The next drug to be approved was lecanemab, which also targets amyloid beta. It received accelerated approval in January 2023; later that year, it received a regular approval, which paved the way ...

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci. 2003 Sep 17;23(24):8532-8. PubMed. Baligács N, Albertini G, Borrie SC, Serneels L, Pridans C ...

When you look at the brain of someone with Alzheimer’s under a microscope, it requires two proteins — beta-amyloid and tau protein, which is thought to occur after amyloid, says Dr. Younes.

There is no ‘amyloid cabal’ in Alzheimer’s research. The scientific conference that had brought us to San Francisco became a lecanemab lovefest — a victory lap for Selkoe and his allies.

An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.

51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Pat ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Bose, Priyom. (2025, February 17). Lecanemab and donanemab slow Alzheimer’s decline, but is the ...

Researchers at the University of Cincinnati have discovered that Leqembi and Kisunla boost levels of a healthy form of amyloid beta (Aβ42) protein in the brain, even as they reduce its more toxic ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease. Using new ...